Kronik Böbrek Hastalığı Olan Tip 2 Diyabetli Hastalarda Aortik Yayılım Hızı ile Subklinik Aterosklerozun Değerlendirilmesi

<!-- /* Font Definitions */ @font-face {font-family:Arial; panose-1:2 11 6 4 2 2 2 2 2 4; mso-font-charset:0; mso-generic-font-family:auto; mso-font-pitch:variable; mso-font-signature:3 0 0 0 1 0;} @font-face {font-family:"MS 明朝"; panose-1:0 0 0 0 0 0 0 0 0 0; mso-font-charset:128; mso-generic-font-family:roman; mso-font-format:other; mso-font-pitch:fixed; mso-font-signature:1 134676480 16 0 131072 0;} @font-face {font-family:"MS 明朝"; panose-1:0 0 0 0 0 0 0 0 0 0; mso-font-charset:128; mso-generic-font-family:roman; mso-font-format:other; mso-font-pitch:fixed; mso-font-signature:1 134676480 16 0 131072 0;} @font-face {font-family:Cambria; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:auto; mso-font-pitch:variable; mso-font-signature:3 0 0 0 1 0;} @font-face {font-family:MinionPro-Regular; panose-1:0 0 0 0 0 0 0 0 0 0; mso-font-alt:"Minion Pro"; mso-font-charset:77; mso-generic-font-family:auto; mso-font-format:other; mso-font-pitch:auto; mso-font-signature:3 0 0 0 1 0;} /* Style Definitions */ p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; margin-bottom:.0001pt; mso-pagination:widow-orphan; font-size:12.0pt; font-family:Cambria; mso-ascii-font-family:Cambria; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:"MS 明朝"; mso-fareast-theme-font:minor-fareast; mso-hansi-font-family:Cambria; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi;} p.TemelParagraf, li.TemelParagraf, div.TemelParagraf {mso-style-name:"\[Temel Paragraf\]"; mso-style-priority:99; mso-style-unhide:no; margin:0cm; margin-bottom:.0001pt; line-height:120%; mso-pagination:none; mso-layout-grid-align:none; text-autospace:none; font-size:12.0pt; font-family:MinionPro-Regular; mso-fareast-font-family:"MS 明朝"; mso-fareast-theme-font:minor-fareast; mso-bidi-font-family:MinionPro-Regular; color:black; mso-ansi-language:EN-GB;} .MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:Cambria; mso-ascii-font-family:Cambria; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:"MS 明朝"; mso-fareast-theme-font:minor-fareast; mso-hansi-font-family:Cambria; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi;} @page WordSection1 {size:612.0pt 792.0pt; margin:72.0pt 90.0pt 72.0pt 90.0pt; mso-header-margin:36.0pt; mso-footer-margin:36.0pt; mso-paper-source:0;} div.WordSection1 {page:WordSection1;} --> Giriş: Diabetes mellitus (DM) ve kronik böbrek hastalığı (KBH) aterosklerozu hızlandırmaktadır. Klinik sonuçları iyileştirmek için, aterosklerozu değerlendiren ve izleyen invaziv olmayan görüntüleme yöntemleri geliştirilmektedir. Son zamanlarda, inen torasik aortun renkli M-mod yayılım hızının [aortik yayılım hızı (AYH)] koroner ve karotisaterosklerozu ile ilişkili olduğu gösterilmiştir. Hastalar ve Yöntem: Çalışma popülasyonu KBH olan tip 2 diyabetli 90 hasta (grup 1) ve yaş ve cinsiyet benzer, normal böbrek fonksiyonlarına sahip tip 2 diyabetli 40 hastadan (grup 2) oluşmaktaydı. Karotis intima-media kalınlığı (KİMK) ve AYH ölçüldü. Bilinen koroner kalp hastalığı veya son dönem böbrek yetmezliği olan hastalar çalışmaya dahil edilmedi. Bulgular: Grup 2 ile karşılaştırıldığında, grup 1 hastalar daha düşük AYH düzeylerine (grup 1= 29.85 ± 3.95 cm/sn ve grup 2= 41.05 ± 3.34 cm/s, p< 0.001) ve daha yüksek KİMK düzeylerine (grup 1= 1.06 ± 0.11 mm ve grup 2= 0.78 ± 0.10 mm, p< 0.001) sahipti. AYH ve KİMK arasında anlamlı korelasyon mevcuttu (r= -0.669, p< 0.001). Sonuç: KBH olan diyabetli hastalar, normal böbrek fonksiyonlu diyabetli hastalara göre daha belirgin AYH ve KIMK değerleri ile belirlenen daha fazla subklinik ateroskleroza sahiptir. Bu basit metodlar, aterosklerozun progresyonunun primer önlenmesi için hasta seçimini geliştirebilir.

Assessment of Subclinical Atherosclerosis with Aortic Velocity Propagation in Patients with Type 2 Diabetes and Chronic Kidney Disease

<!-- /* Font Definitions */ @font-face {font-family:Arial; panose-1:2 11 6 4 2 2 2 2 2 4; mso-font-charset:0; mso-generic-font-family:auto; mso-font-pitch:variable; mso-font-signature:3 0 0 0 1 0;} @font-face {font-family:"MS 明朝"; panose-1:0 0 0 0 0 0 0 0 0 0; mso-font-charset:128; mso-generic-font-family:roman; mso-font-format:other; mso-font-pitch:fixed; mso-font-signature:1 134676480 16 0 131072 0;} @font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:1; mso-generic-font-family:roman; mso-font-format:other; mso-font-pitch:variable; mso-font-signature:0 0 0 0 0 0;} @font-face {font-family:Cambria; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:auto; mso-font-pitch:variable; mso-font-signature:3 0 0 0 1 0;} @font-face {font-family:MinionPro-Regular; panose-1:0 0 0 0 0 0 0 0 0 0; mso-font-alt:"Minion Pro"; mso-font-charset:77; mso-generic-font-family:auto; mso-font-format:other; mso-font-pitch:auto; mso-font-signature:3 0 0 0 1 0;} /* Style Definitions */ p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; margin-bottom:.0001pt; mso-pagination:widow-orphan; font-size:12.0pt; font-family:Cambria; mso-ascii-font-family:Cambria; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:"MS 明朝"; mso-fareast-theme-font:minor-fareast; mso-hansi-font-family:Cambria; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi;} p.TemelParagraf, li.TemelParagraf, div.TemelParagraf {mso-style-name:"\[Temel Paragraf\]"; mso-style-priority:99; mso-style-unhide:no; margin:0cm; margin-bottom:.0001pt; line-height:120%; mso-pagination:none; mso-layout-grid-align:none; text-autospace:none; font-size:12.0pt; font-family:MinionPro-Regular; mso-fareast-font-family:"MS 明朝"; mso-fareast-theme-font:minor-fareast; mso-bidi-font-family:MinionPro-Regular; color:black; mso-ansi-language:EN-GB;} .MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:Cambria; mso-ascii-font-family:Cambria; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:"MS 明朝"; mso-fareast-theme-font:minor-fareast; mso-hansi-font-family:Cambria; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi;} @page WordSection1 {size:612.0pt 792.0pt; margin:72.0pt 90.0pt 72.0pt 90.0pt; mso-header-margin:36.0pt; mso-footer-margin:36.0pt; mso-paper-source:0;} div.WordSection1 {page:WordSection1;} --> Introduction: Diabetes mellitus (DM) and chronic kidney disease (CKD) accelerate the process of atherosclerosis. To improve clinical outcomes, non-invasive imaging modalities have been proposed to measure and monitor atherosclerosis. Recently, colour M-mode-derived propagation velocity of the descending thoracic aorta [aortic velocity propagation (AVP)] has been shown to be associated with coronary and carotid atherosclerosis. Patients and Methods: The study population included 90 patients with type 2 diabetes who had CKD (Group 1) and 40 age- and sex-matched patients with type 2 diabetes who had a normal renal function (Group 2). Carotid intima-media thickness (CIMT) and AVP were measured. Patients with known coronary heart disease or end-stage renal disease were excluded. Results: Compared with Group 1, patients in Group 2 had significantly lower AVP (Group 1=  29.85 ± 3.95 cm/s and Group 2= 41.05 ± 3.34 cm/s, p< 0.001) and higher CIMT (Group 1= 1.06 ± 0.11 mm and Group 2= 0.78 ± 0.10 mm, p< 0.001). There were significant correlations between AVP and CIMT (r= -0.669, p< 0.001). Conclusion: Patients with diabetes who have CKD exhibit more subclinical atherosclerosis, which is determined by more prominent AVP and CMIT, than patients with diabetes who have a normal renal function. These simple methods might improve patient selection for the prevention of primary atherosclerotic progression.

___

  • 1. Grundy SM, Benjamin IJ, Burke GL, Chait A, Eckel RH, Howard BV, et al. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 1999;100:1134-46.
  • 2. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-21.
  • 3. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, et al, European Society of Cardiology Committee for Practice Guidelines. European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2003;10:S1.
  • 4. Niakan E, Harati Y, Rolak LA, Comstock JP, Rokey R. Silent myocardial infarction and diabetic cardiovascular autonomic neuropathy. Arch Intern Med 1986;146:2229.
  • 5. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al; American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003;108:2154.
  • 6. London GM, Guerin AP, Marchais SJ, Pannier B, Safar ME, Day M, et al. Cardiac and arterial interactions in end-stage renal disease. Kidney Int 1996;50:600-8.
  • 7. Gunes Y, Tuncer M, Guntekin U, Ceylan Y, Simsek H, Sahin M, et al. The relation between the color Mmode propagation velocity of the descending aorta and coronary and carotid atherosclerosis and flow-mediated dilatation. Echocardiography 2010;27:300-5.
  • 8. Ognibene A, Grandi G, Lorubbio M, Rapi S, Salvadori B, Terreni A, et al. KDIGO2012 Clinical Practice Guideline CKD classification rules out creatinine clearance 24 hour urine collection? Clin Biochem 2016;49:85-9.
  • 9. Stein JH, Korcarz CE, Hurst RT Lonn E, Kendall CB, Mohler ER, et al; American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography. Carotid intima-media thickness Task Force Endorsed by the Society for vascular Medicine. J Am SocEchocardiogr 2008;21:93-111.
  • 10. London GM, Guerin AP, Marchais SJ, Pannier B, Safar ME, Day M, et al. Cardiac and arterial interactions in end-stage renal disease. Kidney Int 1996;50:600-8.
  • 11. Redberg RF, Vogel RA, Criqui MH, Herrington DM, Lima JA, Roman MJ. 34th Bethesda Conference: Task force #3-- What is the spectrum of current and emerging techniques for the noninvasive measurement of atherosclerosis? J Am Coll Cardiol 2003;41:1886-98.
  • 12. Greenland P, Abrams J, Aurigemma GP, Bond MG, Clark LT, Criqui MH, et al. Prevention conference V: Beyond secondary prevention; identifying the high-risk patient for primary prevention: noninvasive tests of atherosclerotic burden: Writing Group III. Circulation 2000;101:E16-E22.
  • 13. Third report of the National Cholesterol Education Program: Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) Þnal report. Circulation 2002;106:3143-421.
  • 14. Naghavi M, Falk E, Hecht HS, Jamieson MJ, Kaul S, Berman D, et al; SHAPE Task Force. From vulnerable plaque to vulnerable patient Part III: Executive summary of the Screening for Heart Attack Prevention and Education (SHAPE) Task Force report. Am J Cardiol 2006;98:2H-15H.
  • 15. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al; 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007;28: 1462-536.
  • 16. Temelkova-Kurktschiev TS, Koehler C, Leonhardt W, Schaper F, Henkel E, Siegert G, et al. Increased intimal-medial thickness in newly detected type 2 diabetes: Risk factors. Diabetes Care 1999;22:333-8.
  • 17. Paul J, Dasgupta S, Ghosh MK, Shaw K, Roy KS, Niyogi SM. A study of atherosclerosis in patients with chronic renal failure with special reference to carotid artery intima mediathickness. Heart Views 2012; 13:91-6.
  • 18. Nakamura T, Kawagoe Y, Matsuda T, Ueda Y, Shimada N, Ebihara I, et al. Oral ADSORBENT AST-120 decreases carotid intima-media thickness and arterial stiffness in patients with chronic renal failure. Kidney Blood Press Res 2004; 27:121-6.
  • 19. Thenappan T, Ali Raza J, Movahed A. Aortic atheromas: Current concepts and controversies a review of the literature. Echocardiography 2008;25:198-207.
  • 20. Sezgin AT, Sigirci A, Barutcu I, Topal E, Sezgin N, Ozdemir R, et al. Vascular endothelial function in patients with slow coronary flow. Coron Artery Dis 2003;14:155-61.
  • 21. Sahin M, Simsek H, Akyol A, Akdag S, Yaman M, Aydin C, et al. A new echocardiographic parameter of arterial stiffness in end-stage renal disease. Herz 2014;39:749-54.
  • 22. Simsek H, Sahin M, Gunes Y, Dogan A, Gumrukcuoglu HA, Tuncer M. A novel echocardiographic method for the detection of subclinical atherosclerosis in newly diagnosed, untreated type 2 diabetes. Echocardiography 2013; 30:644-8.
Koşuyolu Heart Journal-Cover
  • ISSN: 2149-2972
  • Yayın Aralığı: Yılda 3 Sayı
  • Başlangıç: 1990
  • Yayıncı: Sağlık Bilimleri Üniversitesi, Kartal Koşuyolu Yüksek İhtisas Eğitim ve Araştırma Hastanesi
Sayıdaki Diğer Makaleler

Giant Right Atrium

Mustafa Mert ÖZGÜR, Kaan KIRALİ, Sabit SARIKAYA, Deniz GÜNAY, Murat BÜLENT RABUŞ, Giant Right ATRİUM, Yücel ÖZEN

Pulmoner Tromboendarterektomi Tüm Dünyada Giderek Yaygınlaşmaktadır; Derleme

Mehmet YANARTAŞ, Rezzan DENİZ ACAR, Bedrettin YILDIZELİ

Subclinical Left Ventricular Dysfunction in Chronic Asymptomatic Alcoholic Patients

Akın İZGİ, Arzu KALAYCI, Gönenç KOCABAY, Ayhan ERKOL, Vecih ODUNCU, Taylan AKGÜN, Ruken Bengi BAKKAL, Can YÜCEL KARABAY, Cevat KIRMA, Ahmet GÜLER

Superior Tiroidal Arterin Ana Karotis Arterden Köken Aldığı Hastada Başarılı Karotis Endarterektomi

Tevfik GÜNEŞ, Fırat DURNA, İhsan ALUR, İbrahim GÖKŞİN, Ali Vefa ÖZCAN

Tıkayıcı Mekanik Aort Kapak Trombozu Olan Bir Hastanın Seri Floroskopi Kılavuzluğunda Pıhtı Eritici İlaç ile Tedavisi

Macit Kalçık, Mahmut YESİN, Mustafa Ozan GÜRSOY, Mustafa YILDIZ, Mehmet ÖZKAN

Dev Sağ Atrium

Yücel ÖZEN, Murat Bülent RABUŞ, Sabit SARIKAYA, Deniz GÜNAY, Mustafa Mert ÖZGÜR, Kaan KIRALİ

Süperior Mezenterik Arter Akut Oklüzyonunun Başarılı Tedavisi

Arzu KALAYCI, Vecih ODUNCU, Can Yücel KARABAY, Çetin GEÇMEN, Taylan AKGÜN, İbrahim Akın İZGİ, Cevat KIRMA

Plateletkrit ve Trombosit Dağılım Genişliği Koroner Arter Ektazisinin Bağımsız Öngördürücüsüdür

Hikmet HAMUR, Kamuran KALKAN, Hakan DUMAN, Murtaza Emre DURAKOĞLUGİL, Zafer KÜÇÜKSU, Sinan İNCİ, Erkan YILDIRIM

High Serum Resistin Levels in Coronary Artery Ectasia

İshak Özel TEKİN, Muhammet RAŞİT SAYIN, İbrahim AKPINAR, Mehmet Ali ÇETİNER, Aydan ÖZBAY, Serpil BOZ, Mustafa AYDIN, Turgut KARABAĞ

Musluhittin Emre ERKUŞ, Halil ALTIPARMAK, Zekeriya KAYA, Özgür GÜNEBAKMAZ, Yusuf SEZEN, Recep DEMİRBAĞ